Nanoviricides Inc was incorporated under the laws of the State of Colorado on July 25, 2000 as Edot-com.com, Inc., which was organized for conducting internet retail sales. It is a development stage nano-biopharmaceutical company. The Company's business activities are to discover, develop and commercialize therapeutics to take care of patients suffering from life-threatening viral infections. . It is a development stage company with several drugs in various stages of early development. Its drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (TheraCour), an entity owned and controlled by a stockholder, to which have the necessary exclusive, licenses in perpetuity. Its drugs treats human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. The Company has entered into an Additional License Agreement with TheraCour granting the exclusive licenses in perpetuity for technologies developed by TheraCour for the additional virus types for dengue viruses, japanese encephalitis virus, west nile virus, viruses causing viral conjunctivitis (a disease of the eye) and ocular herpes, and ebola/marburg viruses. Its operations and activities are subject to regulation by numerous government authorities in the United States and other countries.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.